• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Y-mAbs Therapeutics Inc.

    5/30/25 4:13:09 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YMAB alert in real time by email
    DEFA14A 1 ymab-20250530xdefa14a.htm DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

    ​

    ​

    Filed by the Registrant ⌧

    ​

    Filed by a Party other than the Registrant ◻

    ​

    Check the appropriate box:

    ◻

    Preliminary Proxy Statement

    ◻

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ◻

    Definitive Proxy Statement

    ⌧

    Definitive Additional Materials

    ◻

    Soliciting Material under §240.14a-12

    ​

    ​

    ​

    ​

    ​

    Y-MABS THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ⌧

    No fee required.

    ◻

    Fee paid previously with preliminary materials.

    ◻

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    ​

    ​


    GRAPHIC

    1. Election of Class I Director: David N. Gill 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. 3. To approve, on a non-binding advisory vote basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. 4. To conduct any other business properly brought before the meeting or any adjournment or postponement thereof. THE BOARD RECOMMENDS A VOTE “FOR” THE ELECTION OF THE DIRECTOR NOMINEE, AND “FOR” ITEMS 2 AND 3. NOMINEE: This communication presents only an overview of the more complete proxy materials that are available to you on the Internet and is not a form for voting. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. If not requested, you will not receive a paper or e-mail copy of the proxy materials. To facilitate timely delivery please make the request as instructed below before 6/27/2025. Please visit http://www.astproxyportal.com/ast/22412, where the following materials are available for view: • Notice of Annual Meeting of Stockholders • Proxy Statement • Form of Electronic Proxy Card • Annual Report on Form 10-K TO REQUEST MATERIAL: TELEPHONE: 888-Proxy-NA (888-776-9962) or 201-299-6210 (for international callers) E-MAIL: [email protected] WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials TO VOTE: ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the cut-off or meeting date. VIRTUALLY AT THE MEETING: The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit https://meetings.lumiconnect.com/200-405-049-174 (password: ymabs2025) and be sure to have available the 11-digit control number listed above or in your electronic proxy card. TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call. MAIL: You may request a card by following the instructions above. COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER JOHN SMITH 1234 MAIN STREET APT. 203 NEW YORK, NY 10038 Please note that you cannot use this notice to vote by mail. Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting of Y-MABS THERAPEUTICS, INC. To Be Held On: July 11, 2025 at 8:00 a.m. Eastern Time For Stockholders of Record as of May 23, 2025 via the Internet at https://meetings.lumiconnect.com/200-405-049-174 (password: ymabs2025)

    Get the next $YMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YMAB

    DatePrice TargetRatingAnalyst
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    11/18/2024$23.00Outperform
    Oppenheimer
    8/16/2024$20.00Overweight
    Cantor Fitzgerald
    6/28/2024$21.00Buy
    Truist
    5/10/2023$5.00 → $13.00Neutral → Outperform
    Wedbush
    4/3/2023Buy → Neutral
    Guggenheim
    1/27/2023$4.00Equal-Weight → Underweight
    Morgan Stanley
    1/5/2023Outperform → Market Perform
    Cowen
    More analyst ratings

    $YMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

      Company's Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTAIncreased tumor retention and total tumor uptake anticipated by using optimized universal RadiohaptenCompany plans to initiate a Trial 1001 Bridge study (Part 2A) with optimized Radiohapten, "Proteus", in 1H 2026 with data readout in 2H 2026; Part B of Trial 1001 anticipated to initiate with Proteus in 1H 2027 with data readout in 2H 2027Expanded Radiopharmaceutical pipeline to focus on target franchise areas in oncology, with specific prog

      5/28/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

      PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma Research Meeting ("ANR") being held on May 25-28, 2025 in Washington, D.C. The trial in progress poster titled "A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients wit

      5/26/25 10:00:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

      PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will hold a virtual Radiopharmaceutical R&D update at 8:00 a.m. ET on Wednesday, May 28, 2025. During the virtual Radiopharmaceutical R&D update, Y-mAbs will discuss: Part A clinical data from the Company's ongoing Phase 1 GD2-SADA clinical trial (Trial 1001), including pharmacokinetic and dosimetry data; updates around the Company's nonclinical optimization studies

      5/13/25 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care